- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 05.01. | Sanofi's latest autoimmune bispecific pact with AI biotech could reach $2.5B | ||
| 05.01. | Cash-strapped TME Pharma loses partner, prompting eye drug strategy rethink | ||
| 02.01. | NIH instability grows with exit of neuro director, leaving half of institutes under interim leadership | ||
| 02.01. | AbbVie, Gilead gift themselves clinical-stage cancer drugs via licensing deals | ||
| 02.01. | Neuro biotech Nido closes after phase 2 study fails to move needle in rare disease | ||
| 02.01. | J&J junks $1.2B eczema therapy while Genmab clears out cancer drug | ||
| 02.01. | Ultragenyx plans major cost-cutting push after flunking phase 3 brittle bone trials | ||
| 02.01. | Biohaven flunks phase 2 depression trial, adding to concerns for pivotal epilepsy readout | ||
| 23.12.25 | Windtree offloads cardio pipeline, Vaccinex secures $60M funding in continued holiday shopping spree | ||
| 23.12.25 | The top 5 stock picks for biotech in 2026: William Blair | ||
| 23.12.25 | Hope springs toward Parkinson's phase 3 despite divergent stem cell therapy data | ||
| 22.12.25 | 6 people charged in $41M insider trading scheme tied to 2 biotechs | ||
| 22.12.25 | BioMarin quietly discards liver disease candidate after $4.8B Amicus announcement | ||
| 22.12.25 | Gilead pays $35M to license pair of HSV assets from Assembly Bio pact | ||
| 22.12.25 | Boehringer spells out a $448M future for Rectify's ABC kidney disease program | ||
| 22.12.25 | Big Pharma-backed Aktis plans IPO to fund radiopharma trials | ||
| 22.12.25 | Novo Holdings-backed Windward buys rights to Qyuns' clinical-stage immunology bispecific in $700M deal | ||
| 22.12.25 | Ipsen continues ADC push with $1B deal for Simcere's preclinical LRRC15-targeting asset | ||
| 22.12.25 | AstraZeneca flunks phase 3 lung cancer test in further setback to synthetic lethal mechanism | ||
| 22.12.25 | AstraZeneca fronts $100M for Jacobio's clinical-stage pan-KRAS inhibitor | ||
| 19.12.25 | Ipsen's hopes for next-gen rare disease drug dashed by pivotal phase 2 fail | ||
| 19.12.25 | VC Aditum Bio launches new biotech in business play with Fosun Pharma | ||
| 19.12.25 | Merck turns down option to Evaxion's gonorrhea vaccine, prompting Danish biotech to seek other partners | ||
| 19.12.25 | Altimmune eyes phase 3 MASH trial as weight loss deepens | ||
| 19.12.25 | Boehringer walks away from Nxera's phase 2-ready schizophrenia program |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.